From HandWiki
Short description: Atypical Antipsychotic
Structural formula of aripiprazole
Ball-and-stick model of the aripiprazole molecule
Clinical data
Abilify /əˈbɪlɪf/
Trade namesAbilify, Aristada, others
License data
Routes of
By mouth (tablets, dissolving tablets, solution)
IM (including a depot)
Drug classAtypical antipsychotic
ATC code
Legal status
Legal status
Pharmacokinetic data
Protein binding>99%[2][3][4]
MetabolismLiver (mostly via CYP3A4 and 2D6[2][3][4])
Elimination half-life75 hours (active metabolite is 94 hours)[2][3][4]
ExcretionKidney (27%; <1% unchanged)
Feces (60%; 18% unchanged)[2][3][4]
CAS Number
PubChem CID
Chemical and physical data
Molar mass448.39 g·mol−1
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)

Aripiprazole, sold under the brand names Abilify and Aristada among others, is an atypical antipsychotic.[5] It is primarily used in the treatment of schizophrenia and bipolar disorder.[5] Other uses include as an add-on treatment in major depressive disorder, tic disorders and irritability associated with autism.[5] It is taken by mouth or injection into a muscle.[5] A Cochrane review found low-quality evidence of effectiveness in treating schizophrenia.[6]

In adults, side effects with greater than 10% incidence include weight gain, headache, akathisia, insomnia, and gastro-intestinal effects like nausea and constipation, and lightheadedness.[2][3][4][7][8] Side effects in children are similar, and include sleepiness, increased appetite, and stuffy nose.[7] A strong desire to gamble, binge eat, shop, and engage in sexual activity may also occur.[9][10]

Common side effects include vomiting, constipation, sleepiness, dizziness, weight gain and movement disorders.[5] Serious side effects may include neuroleptic malignant syndrome, tardive dyskinesia and anaphylaxis.[5] It is not recommended for older people with dementia-related psychosis due to an increased risk of death.[5] In pregnancy, there is evidence of possible harm to the baby.[5][11] It is not recommended in women who are breastfeeding.[5] It has not been very well studied in people less than 18 years old.[5] The exact mode of action is not entirely clear but may involve effects on dopamine and serotonin.[5]

Aripiprazole was approved for medical use in the United States in 2002.[5] It is available as a generic medication.[12] In 2019, it was the 101st most commonly prescribed medication in the United States, with more than 6 million prescriptions.[13][14] Aripiprazole was discovered in 1988 by scientists at the Japanese firm Otsuka Pharmaceutical.[15][16]

Medical uses

Aripiprazole is primarily used for the treatment of schizophrenia or bipolar disorder.[4][5][17]


The 2016 NICE guidance for treating psychosis and schizophrenia in children and young people recommended aripiprazole as a second line treatment after risperidone for people between 15 and 17 who are having an acute exacerbation or recurrence of psychosis or schizophrenia.[18] A 2014 NICE review of the depot formulation of the drug found that it might have a role in treatment as an alternative to other depot formulations of second generation antipsychotics for people who have trouble taking medication as directed or who prefer it.[19]

A 2014 Cochrane review comparing aripiprazole and other atypical antipsychotics found that it is difficult to determine differences as data quality is poor.[20] A 2011 Cochrane review comparing aripiprazole with placebo concluded that high dropout rates in clinical trials, and a lack of outcome data regarding general functioning, behavior, mortality, economic outcomes, or cognitive functioning make it difficult to definitively conclude that aripiprazole is useful for the prevention of relapse.[6] A Cochrane review found only low quality evidence of effectiveness in treating schizophrenia.[6] Accordingly, part of its methodology on quality of evidence is based on quantity of qualified studies.[21]

A 2013 review found that it is in the middle range of 15 antipsychotics for effectiveness, approximately as effective as haloperidol and quetiapine and slightly more effective than ziprasidone, chlorpromazine, and asenapine, with better tolerability compared to the other antipsychotic drugs (4th best for weight gain, 5th best for extrapyramidal symptoms, best for prolactin elevation, 2nd best for QTc prolongation, and 5th best for sedation). The authors concluded that for acute psychotic episodes aripiprazole results in benefits in some aspects of the condition.[22]

In 2013 the World Federation of Societies for Biological Psychiatry recommended aripiprazole for the treatment of acute exacerbations of schizophrenia as a Grade 1 recommendation and evidence level A.[23]

The British Association for Psychopharmacology similarly recommends that all persons presenting with psychosis receive treatment with an antipsychotic, and that such treatment should continue for at least 1–2 years, as "There is no doubt that antipsychotic discontinuation is strongly associated with relapse during this period". The guideline further notes that "Established schizophrenia requires continued maintenance with doses of antipsychotic medication within the recommended range (Evidence level A)".[24]

The British Association for Psychopharmacology[24] and the World Federation of Societies for Biological Psychiatry suggest that there is little difference in effectiveness between antipsychotics in prevention of relapse, and recommend that the specific choice of antipsychotic be chosen based on each person's preference and side effect profile. The latter group recommends switching to aripiprazole when excessive weight gain is encountered during treatment with other antipsychotics.[23]

Bipolar disorder

Aripiprazole is effective for the treatment of acute manic episodes of bipolar disorder in adults, children, and adolescents.[25][26] Used as maintenance therapy, it is useful for the prevention of manic episodes, but is not useful for bipolar depression.[27][28] Thus, it is often used in combination with an additional mood stabilizer; however, co-administration with a mood stabilizer increases the risk of extrapyramidal side effects.[29]

Major depression

Aripiprazole is an effective add-on treatment for major depressive disorder; however, there is a greater rate of side effects such as weight gain and movement disorders.[30][31][32] The overall benefit is small to moderate and its use appears to neither improve quality of life nor functioning.[30] Aripiprazole may interact with some antidepressants, especially selective serotonin reuptake inhibitors (SSRIs). There are interactions with fluoxetine and paroxetine and lesser interactions with sertraline, escitalopram, citalopram and fluvoxamine, which inhibit CYP2D6, for which aripiprazole is a substrate. CYP2D6 inhibitors increase aripiprazole concentrations to 2-3 times their normal level.[7]


Short-term data (8 weeks) shows reduced irritability, hyperactivity, inappropriate speech, and stereotypy, but no change in lethargic behaviours.[33] Adverse effects include weight gain, sleepiness, drooling and tremors.[33] It is suggested that children and adolescents need to be monitored regularly while taking this medication, to evaluate if this treatment option is still effective after long-term use and note if side effects are worsening. Further studies are needed to understand if this drug is helpful for children after long term use.[33]

Tic disorders

Aripiprazole is approved for the treatment of Tourette's syndrome.[15][34] It is effective, safe, and well-tolerated for this use per systematic reviews and meta-analyses.[35][36][37][38]

Obsessive–compulsive disorder

A 2014 systematic review and meta-analysis concluded that add-on therapy with low dose aripiprazole is an effective treatment for obsessive–compulsive disorder (OCD) that does not improve with selective serotonin reuptake inhibitors (SSRIs) alone.[39] The conclusion was based on the results of two relatively small, short-term trials, each of which demonstrated improvements in symptoms.[39] Risperidone, another second-generation antipsychotic, appears to be superior to aripiprazole for this indication, and is recommended by the 2007 American Psychiatric Association guidelines.[40] However, aripiprazole is cautiously recommended by a 2017 review on antipsychotics for OCD.[41] Aripiprazole is not currently approved for the treatment of OCD and is instead used off-label for this indication.[15]

Adverse effects

In adults, side effects with greater than 10% incidence include weight gain, headache, akathisia, insomnia, and gastro-intestinal effects like nausea and constipation, and lightheadedness.[2][3][4][7][8] Side effects in children are similar, and include sleepiness, increased appetite, and stuffy nose.[7] A strong desire to gamble, binge eat, shop, and engage in sexual activity may also occur.[9][10]

Uncontrolled movement such as restlessness, tremors, and muscle stiffness may occur.[7]


The British National Formulary recommends a gradual withdrawal when discontinuing antipsychotics to avoid acute withdrawal syndrome or rapid relapse.[42] Symptoms of withdrawal commonly include nausea, vomiting, and loss of appetite.[43] Other symptoms may include restlessness, increased sweating, and trouble sleeping.[43] Less commonly there may be a feeling of the world spinning, numbness, or muscle pains.[43] Symptoms generally resolve after a short period of time.[43]

There is tentative evidence that discontinuation of antipsychotics can result in psychosis as a part of a withdrawal syndrome.[44] It may also result in reoccurrence of the condition that is being treated.[45] Rarely tardive dyskinesia can occur when the medication is stopped.[43]


Children or adults who ingested acute overdoses have usually manifested central nervous system depression ranging from mild sedation to coma; serum concentrations of aripiprazole and dehydroaripiprazole in these people were elevated by up to 3-4 fold over normal therapeutic levels; as of 2008 no deaths had been recorded.[46][47]


Aripiprazole is a substrate of CYP2D6 and CYP3A4. Coadministration with medications that inhibit (e.g. paroxetine, fluoxetine) or induce (e.g. carbamazepine) these metabolic enzymes are known to increase and decrease, respectively, plasma levels of aripiprazole.[48][17]

Precautions should be taken in people with an established diagnosis of diabetes mellitus who are started on atypical antipsychotics along with other medications that affect blood sugar levels and should be monitored regularly for worsening of glucose control. The liquid form (oral solution) of this medication may contain up to 15 grams of sugar per dose.[5]

Antipsychotics like aripiprazole and stimulant medications, such as amphetamine, are traditionally thought to have opposing effects to their effects on dopamine receptors: stimulants are thought to increase dopamine in the synaptic cleft, whereas antipsychotics are thought to decrease dopamine. However, it is an oversimplification to state the interaction as such, due to the differing actions of antipsychotics and stimulants in different parts of the brain, as well as the effects of antipsychotics on non-dopaminergic receptors. This interaction frequently occurs in the setting of comorbid attention-deficit hyperactivity disorder (ADHD) (for which stimulants are commonly prescribed) and off-label treatment of aggression with antipsychotics. Aripiprazole has been reported to provide some benefit in improving cognitive functioning in people with ADHD without other psychiatric comorbidities, though the results have been disputed. The combination of antipsychotics like aripiprazole with stimulants should not be considered an absolute contraindication.[49]



Site Ki (nM) Action Ref
SERT 98–1,080 Blocker [52][51]
NET 2,090 Blocker [51]
DAT 3,220 Blocker [51]
5-HT1A 1.7–5.6 Partial agonist
(IA 68%)
5-HT1B 830 ND [51]
5-HT1D 68 ND [51]
5-HT1E 8,000 ND [51]
5-HT2A 3.4–35 Antagonist
(IA 12.7%)
5-HT2B 0.11-0.36 Inverse agonist [51]
5-HT2C 15–180 Partial agonist
(IA 82%)
5-HT3 628 ND [51]
5-HT5A 1,240 ND [51]
5-HT6 214–786 Antagonist [52][51][53]
5-HT7 9.6–39 Antagonist [51][53][52]
α1A 25.9 ND [51][53]
α1B 34.4 ND [51]
α2A 74.3 ND [51][53]
α2B 102 ND [51][53]
α2C 37.9 ND [51][53]
β1 141 ND [51]
β2 163 ND [51]
D1 265–1,170 ND [51]
D2 3.3 Partial agonist
(IA ~25%)
D2L 0.74-1.2 Partial agonist [51][54]
D2S 1.2 Partial agonist [51][54]
D3 0.8–9.7 Partial agonist [52][51]
D4 44–514 Partial agonist [52][51]
D5 95–2,590 ND [52][51]
H1 27.9–61 ND [51][53][52]
H2 >10,000 ND [51]
H3 224 ND [51]
H4 >10,000 ND [51]
M1 6,780 ND [51]
M2 3,510 ND [51]
M3 4,680 ND [51][53]
M4 1,520 ND [51]
M5 2,330 ND [51]
4,001 Antagonist [51]
Values are Ki (nM). The smaller the value, the more strongly the drug binds to the site. All data are for human cloned proteins, except 5-HT3 (rat), D4 (human/rat), H3 (guinea pig), and NMDA/PCP (rat).[51]

Aripiprazole's mechanism of action is different from those of the other FDA-approved atypical antipsychotics (e.g., clozapine, olanzapine, quetiapine, ziprasidone, and risperidone).[55][56][57][58] It shows differential engagement at the dopamine receptor (D2[51]). It appears to show predominantly antagonist activity on postsynaptic D2 receptors and partial agonist activity on presynaptic D2 receptors,[59] D3,[51][60][61] and partially D4[51][56] and is a partial activator of serotonin (5-HT1A,[51][62][63] 5-HT2A,[51] 5-HT2B,[51] 5-HT6, and 5-HT7).[51][58] It also shows lower and likely insignificant effect on histamine (H1), epinephrine/norepinephrine (α), and otherwise dopamine (D4), as well as the serotonin transporter.[51][56] Aripiprazole acts by modulating neurotransmission overactivity of dopamine, which is thought to mitigate schizophrenia symptoms.[64]

As a pharmacologically unique antipsychotic with pronounced functional selectivity, characterization of this dopamine D2 partial agonist (with an intrinsic activity of ~25%)[65] as being similar to a full agonist but at a reduced level of activity presents a misleading oversimplification of its actions; for example, among other effects, aripiprazole has been shown, in vitro, to bind to and/or induce receptor conformations (i.e. facilitate receptor shapes) in such a way as to not only prevent receptor internalization (and, thus, lower receptor density) but even to lower the rate of receptor internalization below that of neurons not in the presence of agonists (including dopamine) or antagonists.[66] It is often the nature of partial agonists, including aripiprazole, to display a stabilizing effect (such as on mood in this case) with agonistic activity when there are low levels of endogenous neurotransmitters (such as dopamine) and antagonistic activity in the presence of high levels of agonists associated with events such as mania, psychosis, and drug use. In addition to aripiprazole's partial agonism and functional selectivity characteristics, its effectiveness may be mediated by its very high dopamine D2 receptor occupancy (approximately 32%, 53%, 72%, 80%, and 97% at daily dosages of 0.5 mg, 1 mg, 2 mg, 10 mg, and 40 mg respectively)[67][68] as well as balanced selectivity for pre- and postsynaptic receptors (as suggested by its equal affinity for both D2S and D2L receptor forms).[54] Aripiprazole has been characterized as possessing predominantly antagonistic activity on postsynaptic D2 receptors and partial agonist activity on presynaptic D2 receptors;[59] however, while this explanation intuitively explains the drug's efficacy as an antipsychotic, as degree of agonism is a function of more than a drug's inherent properties as well as in vitro demonstration of aripiprazole's partial agonism in cells expressing postsynaptic (D2L) receptors, it was noted that "It is unlikely that the differential actions of aripiprazole as an agonist, antagonist, or partial agonist were entirely due to differences in relative D2 receptor expression since aripiprazole was an antagonist in cells with the highest level of expression (4.6 pmol/mg) and a partial agonist in cells with an intermediate level of expression (0.5–1 pmol/mg). Instead, the current data are most parsimoniously explained by the 'functional selectivity' hypothesis of Lawler et al (1999)".[69] Aripiprazole is also a partial agonist of the D3 receptor.[51] In healthy human volunteers, D2 and D3 receptor occupancy levels are high, with average levels ranging between approximately 71% at 2 mg/day to approximately 96% at 40 mg/day.[60][61] Most atypical antipsychotics bind preferentially to extrastriatal receptors, but aripiprazole appears to be less preferential in this regard, as binding rates are high throughout the brain.[70]

Aripiprazole is also a partial agonist of the serotonin 5-HT1A receptor (intrinsic activity = 68%).[51][62][63]Casting doubt on the significance of aripiprazole's agonism of 5-HT1A receptors, a PET scan study of 12 patients receiving doses ranging from 10 to 30 mg found 5-HT1A receptor occupancy to be only 16% compared to ~90% for D2.[71] It is a very weak partial agonist of the 5-HT2A receptor (intrinsic activity = 12.7%),[51] and like other atypical antipsychotics, displays a functional antagonist profile at this receptor.[51] The drug differs from other atypical antipsychotics in having higher affinity for the D2 receptor than for the 5-HT2A receptor.[63] At the 5-HT2B receptor, aripiprazole has both great binding affinity and acts as a potent inverse agonist, "Aripiprazole decreased PI hydrolysis from a basal level of 61% down to a low of 30% at 1000 nM, with an EC50 of 11 nM".[51] Unlike other antipsychotics, aripiprazole is a high-efficacy partial agonist of the 5-HT2C receptor (intrinsic activity = 82%) and with relatively weak affinity;[51] this property may underlie the minimal weight gain seen in the course of therapy.[72] At the 5-HT7 receptor, aripiprazole is a very weak partial agonist with barely measurable intrinsic activity, and hence is a functional antagonist of this receptor.[51][58] Aripiprazole also shows lower but likely clinically insignificant affinity for a number of other sites, such as the histamine H1, α-adrenergic, and dopamine D4 receptors as well as the serotonin transporter, while it has negligible affinity for the muscarinic acetylcholine receptors.[51][56]

Since the actions of aripiprazole differ markedly across receptor systems aripiprazole was sometimes an antagonist (e.g. at 5-HT6 and D2L), sometimes an inverse agonist (e.g. 5-HT2B), sometimes a partial agonist (e.g. D2L), and sometimes a full agonist (D3, D4). Aripiprazole was frequently found to be a partial agonist, with an intrinsic activity that could be low (D2L, 5-HT2A, 5-HT7), intermediate (5-HT1A), or high (D4, 5-HT2C). This mixture of agonist actions at D2-dopamine receptors is consistent with the hypothesis that aripiprazole has 'functionally selective' actions.[73] The 'functional-selectivity' hypothesis proposes that a mixture of agonist/partial agonist/antagonist actions are likely. According to this hypothesis, agonists may induce structural changes in receptor conformations that are differentially 'sensed' by the local complement of G proteins to induce a variety of functional actions depending upon the precise cellular milieu. The diverse actions of aripiprazole at D2-dopamine receptors are clearly cell-type specific (e.g. agonism, antagonism, partial agonism), and are most parsimoniously explained by the 'functional selectivity' hypothesis.[51]

Since 5-HT2C receptors have been implicated in the control of depression, OCD, and appetite, agonism at the 5-HT2C receptor might be associated with therapeutic potential in obsessive compulsive disorder, obesity, and depression. 5-HT2C agonism has been demonstrated to induce anorexia via enhancement of serotonergic neurotransmission via activation of 5-HT2C receptors; it is conceivable that the 5-HT2C agonist actions of aripiprazole may, thus, be partly responsible for the minimal weight gain associated with this compound in clinical trials. In terms of potential action as an antiobsessional agent, it is worthwhile noting that a variety of 5-HT2A/5-HT2C agonists have shown promise as antiobsessional agents, yet many of these compounds are hallucinogenic, presumably due to 5-HT2A activation. Aripiprazole has a favorable pharmacological profile in being a 5-HT2A antagonist and a 5-HT2C partial agonist. Based on this profile, one can predict that aripiprazole may have antiobsessional and anorectic actions in humans.[51]

Wood and Reavill's (2007) review of published and unpublished data proposed that, at therapeutically relevant doses, aripiprazole may act essentially as a selective partial agonist of the D2 receptor without significantly affecting the majority of serotonin receptors.[59] A positron emission tomography imaging study found that 10 to 30 mg/day aripiprazole resulted in 85 to 95% occupancy of the D2 receptor in various brain areas (putamen, caudate, ventral striatum) versus 54 to 60% occupancy of the 5-HT2A receptor and only 16% occupancy of the 5-HT1A receptor.[74][63] It has been suggested that the low occupancy of the 5-HT1A receptor by aripiprazole may have been an erroneous measurement however.[75]

Aripiprazole acts by modulating neurotransmission overactivity on the dopaminergic mesolimbic pathway, which is thought to be a cause of positive schizophrenia symptoms.[64] Due to its agonist activity on D2 receptors, aripiprazole may also increase dopaminergic activity to optimal levels in the mesocortical pathways where it is reduced.[64]


Aripiprazole displays linear kinetics and has an elimination half-life of approximately 75 hours. Steady-state plasma concentrations are achieved in about 14 days. Cmax (maximum plasma concentration) is achieved 3–5 hours after oral dosing. Bioavailability of the oral tablets is about 90% and the drug undergoes extensive hepatic metabolization (dehydrogenation, hydroxylation, and N-dealkylation), principally by the enzymes CYP2D6 and CYP3A4. Its only known active metabolite is dehydro-aripiprazole, which typically accumulates to approximately 40% of the aripiprazole concentration. The parenteral drug is excreted only in traces, and its metabolites, active or not, are excreted via feces and urine.[56][17]


Aripiprazole is a phenylpiperazine and is chemically related to nefazodone, etoperidone, and trazodone.[76][77] It is unusual in having twelve known crystalline polymorphs.[78][79]


Abilify (aripiprazole) 10 mg tablets (TR)

Aripiprazole was discovered by scientists at Otsuka Pharmaceutical and was called OPC-14597.[15][80] It was first published in 1995.[80][81] Otsuka initially developed the drug, and partnered with Bristol-Myers Squibb (BMS) in 1999 to complete development, obtain approvals, and market aripiprazole.[82]

It was approved by the U.S. Food and Drug Administration (FDA) for schizophrenia in November 2002, and the European Medicines Agency in June 2004; for acute manic and mixed episodes associated with bipolar disorder on October 1, 2004; as an adjunct for major depressive disorder on November 20, 2007;[83] and to treat irritability in children with autism on 20 November 2009.[84] Likewise it was approved for use as a treatment for schizophrenia by the TGA of Australia in May 2003.[7]

Aripiprazole has been approved by the FDA for the treatment of both acute manic and mixed episodes, in people older than ten years.[85]

In 2006, the FDA required manufacturers to add a black box warning to the label, warning that older people who were given the drug for dementia-related psychosis were at greater risk of death.[86]

In 2007, aripiprazole was approved by the FDA for the treatment of unipolar depression when used adjunctively with an antidepressant medication.[87] That same year, BMS settled a case with the U.S. government in which it paid $515 million; the case covered several drugs but the focus was on BMS's off-label marketing of aripiprazole for children and older people with dementia.[88]

In 2011 Otsuka and Lundbeck signed a collaboration to develop a depot formulation of apripiprazole.[89]

As of 2013, Abilify had annual sales of US$7 billion.[90] In 2013 BMS returned marketing rights to Otsuka, but kept manufacturing the drug.[91] Also in 2013, Otsuka and Lundbeck received U.S. and European marketing approval for an injectable depot formulation of aripiprazole.[92][93]

Otsuka's U.S. patent on aripiprazole expired on October 20, 2014, but due to a pediatric extension, a generic did not become available until April 20, 2015.[85] Barr Laboratories (now Teva Pharmaceuticals) initiated a patent challenge under the Hatch-Waxman Act in March 2007.[94] On November 15, 2010, this challenge was rejected by the U.S. District Court in New Jersey.[95]

Otsuka's European patent EP0367141 which would have expired on 26 October 2009, was extended by a Supplementary Protection Certificate (SPC) to 26 October 2014.,[96] The UK Intellectual Property Office decided[97] on 4 March 2015 that the SPC could not be further extended by six months under Regulation (EC) No 1901/2006. Even if the decision is successfully appealed, protection in Europe will not extend beyond 26 April 2015.

From April 2013 to March 2014, sales of Abilify amounted to almost $6.9 billion.[98]

In April 2015, the FDA announced the first generic versions.[99][100] In October 2015, aripiprazole lauroxil, a prodrug of aripiprazole that is administered via intramuscular injection once every four to six weeks for the treatment of schizophrenia, was approved by the FDA.[101][102]

In 2016, BMS settled cases with 42 U.S. states that had charged BMS with off-label marketing to older people with dementia; BMS agreed to pay $19.5 million.[86][103]

In November 2017, the FDA approved Abilify MyCite, a digital pill containing a sensor intended to record when its consumer takes their medication.[104][105]

Society and culture

Regulatory status

Regulatory administration (country)[106][107][108] Schizophrenia Acute mania Bipolar maintenance Major depressive disorder (as an adjunct) Irritability in autism
Food and Drug Administration (US) Yes Yes Yes (as an adjunct to lithium/valproate) Yes Yes (children and adolescents)
Therapeutic Goods Administration (Australia ) Yes Yes (as an adjunct to lithium/valproate) Yes No No
Medicines and Healthcare products Regulatory Agency (United Kingdom ) Yes Yes Yes (to prevent mania) No No


Aripiprazole has been described as the prototypical third-generation antipsychotic, as opposed to first-generation (typical) antipsychotics like haloperidol and second-generation (atypical) antipsychotics like clozapine.[109] It has received this classification due to its partial agonism of dopamine receptors, and is the first of its kind in this regard among antipsychotics, which before aripiprazole acted only as dopamine receptor antagonists.[109] The introduction of aripiprazole has led to a paradigm shift from a dopamine antagonist-based approach to a dopamine agonist-based approach for antipsychotic drug development.[109]


Attention deficit hyperactivity disorder

Aripiprazole was under development for the treatment of attention-deficit hyperactivity disorder (ADHD), but development for this indication was discontinued.[15] A 2017 meta review found only preliminary evidence (studies with small sample sizes and methodological problems) for aripiprazole in the treatment of ADHD.[110] A 2013 systematic review of aripiprazole for ADHD similarly reported that there is insufficient evidence of effectiveness to support aripiprazole as a treatment for the condition.[111] Although all 6 non-controlled open-label studies in the review reported effectiveness, two small randomized controlled trials found that aripiprazole did not significantly decrease ADHD symptoms.[111] A high rate of adverse effects with aripiprazole such as weight gain, sedation, and headache was noted.[111] Most research on aripiprazole for ADHD is in children and adolescents.[111][110] Evidence on aripiprazole specifically for adult ADHD appears to be limited to a single case report.[112][113]

Substance dependence

Aripiprazole has been studied for the treatment of amphetamine dependence and other substance use disorders, but more research is needed to support aripiprazole for these potential uses.[114][115][116][117] Available evidence of aripiprazole for amphetamine dependence is mixed.[114][115][116][117] Some studies have reported attenuation of the effects of amphetamines by aripiprazole, whereas other studies have reported both enhancement of the effects of amphetamines and increased use of amphetamines by aripiprazole.[114][115][116][117] As such, aripiprazole may not only be ineffective but potentially harmful for treatment of amphetamine dependence, and caution is warranted with regard to its use for such purposes.[114][115][116][117]

Other uses

Aripiprazole is under development for the treatment of agitation and pervasive child development disorders.[15] As of May 2021, it is in phase 3 clinical trials for these indications.[15]


  1. "Aripiprazole Use During Pregnancy". 22 August 2019. 
  2. 2.0 2.1 2.2 2.3 2.4 2.5 2.6 "Abilify (aripiprazole) tablet Abilify (aripiprazole) solution Abilify Discmelt (aripiprazole) tablet, orally disintegrating Abilify (aripiprazole) injection, solution [Otsuka America Pharmaceutical, Inc."]. Otsuka America Pharmaceutical, Inc.. April 2013. 
  3. 3.0 3.1 3.2 3.3 3.4 3.5 3.6 "Abilify Tablets, Orodispersible Tablets, Oral Solution - Summary of Product Characteristics (SPC)". Otsuka Pharmaceuticals (UK) Ltd. 20 September 2013. 
  4. 4.0 4.1 4.2 4.3 4.4 4.5 4.6 4.7 "ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS". Otsuka Pharmaceutical Europe Ltd.. 
  5. 5.00 5.01 5.02 5.03 5.04 5.05 5.06 5.07 5.08 5.09 5.10 5.11 5.12 5.13 "Aripiprazole, ARIPiprazole Lauroxil Monograph for Professionals". American Society of Health-System Pharmacists. 
  6. 6.0 6.1 6.2 "Aripiprazole versus placebo for schizophrenia". The Cochrane Database of Systematic Reviews (8): CD006622. August 2011. doi:10.1002/14651858.CD006622.pub2. PMID 21833956. 
  7. 7.0 7.1 7.2 7.3 7.4 7.5 7.6 "Product Information for Abilify Aripiprazole Tablets & Orally Disintegrating Tablets". Bristol-Myers Squibb Australia Pty Ltd. 1 November 2012. 
  8. 8.0 8.1 "Abilify Discmelt, Abilify Maintena (aripiprazole) dosing, indications, interactions, adverse effects, and more". WebMD. 
  9. 9.0 9.1 "Aripiprazole (Abilify, Abilify Maintena, Aristada): Drug Safety Communication - FDA Warns About New Impulse-control Problems". 3 May 2016. 
  10. 10.0 10.1 "Pathological Gambling Associated With Aripiprazole or Dopamine Replacement Therapy: Do Patients Share the Same Features? A Review". J Clin Psychopharmacol 36 (1): 63–70. 2016. doi:10.1097/JCP.0000000000000444. PMID 26658263. 
  11. "Prescribing medicines in pregnancy database". 3 March 2014. 
  12. British national formulary: BNF 76 (76th ed.). Pharmaceutical Press. 2018. pp. 392. ISBN 9780857113382. 
  13. "The Top 300 of 2019". 
  14. "Aripiprazole - Drug Usage Statistics". 
  15. 15.0 15.1 15.2 15.3 15.4 15.5 15.6 "Aripiprazole". AdisInsight. 
  16. Behere, Prakash B.; Das, Anweshak; Behere, Aniruddh P. (2018). Clinical Psychopharmacology: An Update. Springer. p. 66. ISBN 9789811320927. 
  17. 17.0 17.1 17.2 "Abilify- aripiprazole tablet Abilify- aripiprazole solution Abilify- aripiprazole tablet, orally disintegrating Abilify- aripiprazole injection, solution". 
  18. "Psychosis and schizophrenia in children and young people: recognition and management | Guidance and guidelines | NICE". NICE. October 2016. 
  19. "Schizophrenia: aripiprazole prolonged-release suspension for injection | Guidance and guidelines | NICE". NICE. 24 July 2013. 
  20. "Aripiprazole versus other atypical antipsychotics for schizophrenia". The Cochrane Database of Systematic Reviews (1): CD006569. January 2014. doi:10.1002/14651858.CD006569.pub5. PMID 24385408. 
  21. "Levels of Evidence". Cochrane. 
  22. "Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis". Lancet 382 (9896): 951–62. September 2013. doi:10.1016/S0140-6736(13)60733-3. PMID 23810019. 
  23. 23.0 23.1 "World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects". The World Journal of Biological Psychiatry 14 (1): 2–44. February 2013. doi:10.3109/15622975.2012.739708. PMID 23216388. 
  24. 24.0 24.1 "Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology". Journal of Psychopharmacology 25 (5): 567–620. May 2011. doi:10.1177/0269881110391123. PMID 21292923. 
  25. "Bipolar disorder: assessment and management". UK National Institute for Health and Care Excellence (NICE). "1.1 Care for adults, children and young people across all phases of bipolar disorder" 
  26. "Aripiprazole alone or in combination for acute mania". The Cochrane Database of Systematic Reviews 12 (12): CD005000. December 2013. doi:10.1002/14651858.CD005000.pub2. PMID 24346956. 
  27. "Second generation antipsychotics in the treatment of bipolar depression: a systematic review and meta-analysis". Journal of Psychopharmacology 26 (5): 603–17. May 2012. doi:10.1177/0269881111408461. PMID 21940761. 
  28. "Maintenance therapies in bipolar disorders". Bipolar Disorders 14 Suppl 2: 51–65. May 2012. doi:10.1111/j.1399-5618.2012.00992.x. PMID 22510036. 
  29. "Combination of aripiprazole with mood stabilizers for the treatment of bipolar disorder: from acute mania to long-term maintenance". Expert Opinion on Pharmacotherapy 13 (14): 2027–36. October 2012. doi:10.1517/14656566.2012.719876. PMID 22946707. 
  30. 30.0 30.1 "Adjunctive atypical antipsychotic treatment for major depressive disorder: a meta-analysis of depression, quality of life, and safety outcomes". PLOS Medicine 10 (3): e1001403. Mar 12, 2013. doi:10.1371/journal.pmed.1001403. PMID 23554581. 
  31. "Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials". The American Journal of Psychiatry 166 (9): 980–91. September 2009. doi:10.1176/appi.ajp.2009.09030312. PMID 19687129. 
  32. "Second-generation antipsychotics for major depressive disorder and dysthymia". The Cochrane Database of Systematic Reviews (12): CD008121. December 2010. doi:10.1002/14651858.CD008121.pub2. PMID 21154393. 
  33. 33.0 33.1 33.2 "Aripiprazole for autism spectrum disorders (ASD)". The Cochrane Database of Systematic Reviews (6): CD009043. June 2016. doi:10.1002/14651858.CD009043.pub3. PMID 27344135. 
  34. "Aripiprazole in treatment of Gilles de la Tourette syndrome - New therapeutic option". Neurol Neurochir Pol 52 (1): 84–87. 2018. doi:10.1016/j.pjnns.2017.10.015. PMID 29154107. 
  35. "The efficacy and safety of aripiprazole for tic disorders in children and adolescents: A systematic review and meta-analysis". Psychiatry Res 254: 24–32. August 2017. doi:10.1016/j.psychres.2017.04.013. PMID 28441584. 
  36. "Safety and efficacy of aripiprazole for the treatment of pediatric Tourette syndrome and other chronic tic disorders". Pediatric Health Med Ther 7: 57–64. 2016. doi:10.2147/PHMT.S87121. PMID 29388585. 
  37. "Aripiprazole for Tourette's syndrome: a systematic review and meta-analysis". Hum Psychopharmacol 31 (1): 11–8. January 2016. doi:10.1002/hup.2498. PMID 26310194. 
  38. "Aripiprazole for the treatment of tic disorders in children: a systematic review and meta-analysis". BMC Psychiatry 15: 179. July 2015. doi:10.1186/s12888-015-0504-z. PMID 26220447. 
  39. 39.0 39.1 "Atypical antipsychotic augmentation in SSRI treatment refractory obsessive-compulsive disorder: a systematic review and meta-analysis". BMC Psychiatry 14 (1): 317. November 2014. doi:10.1186/s12888-014-0317-5. PMID 25432131. 
  40. "Practice guideline for the treatment of patients with obsessive-compulsive disorder". Am J Psychiatry 164 (7 Suppl): 5–53. July 2007. PMID 17849776. 
  41. "The Place of Antipsychotics in the Therapy of Anxiety Disorders and Obsessive-Compulsive Disorders". Current Psychiatry Reports 19 (12): 103. November 2017. doi:10.1007/s11920-017-0847-x. PMID 29110139. 
  42. Joint Formulary Committee, BMJ, ed (March 2009). "4.2.1". British National Formulary (57 ed.). United Kingdom: Royal Pharmaceutical Society of Great Britain. p. 192. ISBN 978-0-85369-845-6. "Withdrawal of antipsychotic drugs after long-term therapy should always be gradual and closely monitored to avoid the risk of acute withdrawal syndromes or rapid relapse." 
  43. 43.0 43.1 43.2 43.3 43.4 Haddad, Peter; Haddad, Peter M.; Dursun, Serdar; Deakin, Bill (2004). Adverse Syndromes and Psychiatric Drugs: A Clinical Guide. OUP Oxford. pp. 207–216. ISBN 9780198527480. 
  44. "Does antipsychotic withdrawal provoke psychosis? Review of the literature on rapid onset psychosis (supersensitivity psychosis) and withdrawal-related relapse". Acta Psychiatrica Scandinavica 114 (1): 3–13. July 2006. doi:10.1111/j.1600-0447.2006.00787.x. PMID 16774655. 
  45. Sacchetti, Emilio; Vita, Antonio; Siracusano, Alberto; Fleischhacker, Wolfgang (2013). Adherence to Antipsychotics in Schizophrenia. Springer Science & Business Media. p. 85. ISBN 9788847026797. 
  46. Baselt, Randall C. (2008). Disposition of Toxic Drugs and Chemicals in Man (8th ed.). Foster City, CA: Biomedical Publications. pp. 105–6. ISBN 978-0-9626523-7-0. 
  47. "Postmortem Femoral Blood Reference Concentrations of Aripiprazole, Chlorprothixene, and Quetiapine". Journal of Analytical Toxicology 39 (1): 41–4. Jan 2015. doi:10.1093/jat/bku121. PMID 25342720. 
  48. "Abilify (Aripiprazole) - Warnings and Precautions". 14 February 2007. 
  49. "The dopamine dilemma: using stimulants and antipsychotics concurrently". Psychiatry 7 (6): 18–23. June 2010. PMID 20622942. 
  50. "PDSP Ki Database". University of North Carolina at Chapel Hill and the United States National Institute of Mental Health. 
  51. 51.00 51.01 51.02 51.03 51.04 51.05 51.06 51.07 51.08 51.09 51.10 51.11 51.12 51.13 51.14 51.15 51.16 51.17 51.18 51.19 51.20 51.21 51.22 51.23 51.24 51.25 51.26 51.27 51.28 51.29 51.30 51.31 51.32 51.33 51.34 51.35 51.36 51.37 51.38 51.39 51.40 51.41 51.42 51.43 51.44 51.45 51.46 51.47 51.48 51.49 51.50 51.51 51.52 51.53 51.54 51.55 51.56 51.57 "Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology". Neuropsychopharmacology 28 (8): 1400–11. 2003. doi:10.1038/sj.npp.1300203. PMID 12784105. 
  52. 52.0 52.1 52.2 52.3 52.4 52.5 52.6 52.7 52.8 52.9 "Aripiprazole: a partial dopamine D2 receptor agonist antipsychotic". Expert Opin Investig Drugs 12 (4): 655–62. 2003. doi:10.1517/13543784.12.4.655. PMID 12665420. 
  53. 53.00 53.01 53.02 53.03 53.04 53.05 53.06 53.07 53.08 53.09 53.10 "H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs". Neuropsychopharmacology 28 (3): 519–26. 2003. doi:10.1038/sj.npp.1300027. PMID 12629531. 
  54. 54.0 54.1 54.2 Tadori, Yoshihiro; Miwa, Takashi; Tottori, Katsura; Burris, Kevin D.; Stark, Arlene; Mori, Toyoki; Kikuchi, Tetsuro (May 16, 2005). "Aripiprazole's low intrinsic activities at human dopamine D2L and D2S receptors render it a unique antipsychotic". European Journal of Pharmacology 515 (1–3): 10–19. doi:10.1016/j.ejphar.2005.02.051. PMID 15894311. Retrieved 11 July 2022. 
  55. "How can antipsychotics cause Diabetes Mellitus? Insights based on receptor-binding profiles, humoral factors and transporter proteins". European Psychiatry 24 (3): 164–70. April 2009. doi:10.1016/j.eurpsy.2009.01.001. PMID 19285836. 
  56. 56.0 56.1 56.2 56.3 56.4 "Abilify (Aripiprazole) - Clinical Pharmacology". 14 February 2007. 
  57. Brunton, Laurence (2011). Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th Edition. China: McGraw-Hill. pp. 406–410. ISBN 978-0-07-162442-8. 
  58. 58.0 58.1 58.2 "Aripiprazole: a novel atypical antipsychotic drug with a uniquely robust pharmacology". CNS Drug Reviews 10 (4): 317–36. 2004. doi:10.1111/j.1527-3458.2004.tb00030.x. PMID 15592581. 
  59. 59.0 59.1 59.2 "Aripiprazole acts as a selective dopamine D2 receptor partial agonist". Expert Opin Investig Drugs 16 (6): 771–5. 2007. doi:10.1517/13543784.16.6.771. PMID 17501690. 
  60. 60.0 60.1 "Dose-occupancy study of striatal and extrastriatal dopamine D2 receptors by aripiprazole in schizophrenia with PET and [18F]fallypride". Neuropsychopharmacology 33 (13): 3111–25. December 2008. doi:10.1038/npp.2008.33. PMID 18418366. 
  61. 61.0 61.1 "Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]raclopride". Neuropsychopharmacology 27 (2): 248–59. August 2002. doi:10.1016/S0893-133X(02)00304-4. PMID 12093598. 
  62. 62.0 62.1 "The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor". European Journal of Pharmacology 441 (3): 137–40. April 2002. doi:10.1016/S0014-2999(02)01532-7. PMID 12063084. 
  63. 63.0 63.1 63.2 63.3 "Differential effects of aripiprazole on D(2), 5-HT(2), and 5-HT(1A) receptor occupancy in patients with schizophrenia: a triple tracer PET study". Am J Psychiatry 164 (9): 1411–7. 2007. doi:10.1176/appi.ajp.2007.06091479. PMID 17728427. 
  64. 64.0 64.1 64.2 "Third generation antipsychotic drugs: partial agonism or receptor functional selectivity?". Current Pharmaceutical Design 16 (5): 488–501. May 2010. doi:10.2174/138161210790361461. PMID 19909227. 
  65. Burris, Kevin D.; Molski, Thaddeus F.; Xu, Cen; Ryan, Elaine; Tottori, Katsura; Kikuchi, Tetsuro; Yocca, Frank D.; Molinoff, Perry B. (July 2002). "Aripiprazole, a Novel Antipsychotic, Is a High-Affinity Partial Agonist at Human Dopamine D2 Receptors". Journal of Pharmacology and Experimental Therapeutics 302 (1): 381–389. doi:10.1124/jpet.102.033175. PMID 12065741. Retrieved 8 July 2022. 
  66. Urban, Jonathan D; Vargas, Gabriel A; von Zastrow, Mark; Mailman, Richard B (Mar 22, 2006). "Aripiprazole has Functionally Selective Actions at Dopamine D2 Receptor-Mediated Signaling Pathways". Neuropsychopharmacology 32 (1): 67–77. doi:10.1038/sj.npp.1301071. PMID 16554739. Retrieved 8 July 2022. 
  67. Yokoi, Fuji; Gründer, Gerhard; Biziere, Kathleen; Stephane, Massoud; Dogan, Ahmet S.; Dannals, Robert F.; Ravert, Hayden; Suri, Ajit et al. (Feb 5, 2002). "Dopamine D2 and D3 Receptor Occupancy in Normal Humans Treated with the Antipsychotic Drug Aripiprazole (OPC 14597): A Study Using Positron Emission Tomography and [11CRaclopride"]. Neuropsychopharmacology 27 (2): 248–259. doi:10.1016/S0893-133X(02)00304-4. PMID 12093598. Retrieved 9 July 2022. 
  68. Kegeles, Lawrence S; Slifstein, Mark; Frankle, W Gordon; Xu, Xiaoyan; Hackett, Elizabeth; Bae, Sung-A; Gonzales, Robyn; Kim, Jong-Hoon et al. (Apr 16, 2008). "Dose–Occupancy Study of Striatal and Extrastriatal Dopamine D2 Receptors by Aripiprazole in Schizophrenia with PET and [18FFallypride"]. Neuropsychopharmacology 33 (13): 3111–3125. doi:10.1038/npp.2008.33. PMID 18418366. Retrieved 8 July 2022. 
  69. Shapiro, David A; Renock, Sean; Arrington, Elaine; Chiodo, Louis A; Liu, Li-Xin; Sibley, David R; Roth, Bryan L; Mailman, Richard (Mar 27, 2003). "Aripiprazole, A Novel Atypical Antipsychotic Drug with a Unique and Robust Pharmacology". Neuropsychopharmacology 28 (8): 1400–1411. doi:10.1038/sj.npp.1300203. PMID 12784105. Retrieved 8 July 2022. 
  70. "In This Issue". Am J Psychiatry 165 (8): A46. August 2008. doi:10.1176/appi.ajp.2008.165.8.A46. 
  71. Mamo, David; Graff, Ariel; Mizrahi, Romina; Shammi, M.; Romeyer, Françoise; Kapur, Shitij (Sep 2007). "Differential Effects of Aripiprazole on D 2 , 5-HT 2 , and 5-HT 1A Receptor Occupancy in Patients With Schizophrenia: A Triple Tracer PET Study". The American Journal of Psychiatry 164 (9): 1411–1417. doi:10.1176/appi.ajp.2007.06091479. PMID 17728427. Retrieved 21 August 2022. 
  72. "Distinct functional profiles of aripiprazole and olanzapine at RNA edited human 5-HT2C receptor isoforms". Biochemical Pharmacology 71 (4): 521–9. February 2006. doi:10.1016/j.bcp.2005.11.007. PMID 16336943. 
  73. "Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes". Neuropsychopharmacology 20 (6): 612–27. June 1999. doi:10.1016/S0893-133X(98)00099-2. PMID 10327430. 
  74. "Clinical pharmacology of atypical antipsychotics: an update". Excli J 13: 1163–91. 2014. PMID 26417330. 
  75. "Aripiprazole: what is the role of dopamine D(2) receptor partial agonism?". Am J Psychiatry 164 (9): 1310–2. 2007. doi:10.1176/appi.ajp.2007.07071043. PMID 17728411. 
  76. Akritopoulou-Zanze, Irini (2012). "6. Arylpiperazine-Based 5-HT1A Receptor Partial Agonists and 5-HT2A Antagonists for the Treatment of Autism, Depression, Anxiety, Psychosis, and Schizophrenia". in Dinges, Jürgen; Lamberth, Clemens. Bioactive heterocyclic compound classes pharmaceuticals. Weinheim: Wiley-VCH. ISBN 978-3-527-66445-0. 
  77. Dörwald, Florencioa Zaragoza, ed (2012). "46. Arylalkylamines". Lead optimization for medicinal chemists: pharmacokinetic properties of functional groups and organic compounds. Weinheim: Wiley-VCH. ISBN 978-3-527-64564-0. 
  78. Serezhkin, Viktor N.; Savchenkov, Anton V. (2020). "Application of the Method of Molecular Voronoi–Dirichlet Polyhedra for Analysis of Noncovalent Interactions in Aripiprazole Polymorphs". Crystal Growth & Design 20 (3): 1997–2003. doi:10.1021/acs.cgd.9b01645. 
  79. Warren, Lisette R; McGowan, Evana; Renton, Margaret; Morrison, Carole A; Funnell, Nicholas P (2021). "Direct evidence for distinct colour origins in ROY polymorphs". Chemical Science 12 (38): 12711–12718. doi:10.1039/d1sc04051k. PMID 34703557. 
  80. 80.0 80.1 "Aripiprazole". Nature Reviews. Drug Discovery 2 (6): 427–8. June 2003. doi:10.1038/nrd1114. PMID 12790153. 
  81. "7-(4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-2(1H)-quinolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity". The Journal of Pharmacology and Experimental Therapeutics 274 (1): 329–36. July 1995. PMID 7616416. 
  82. "B-MS reveals Ph III aripiprazole data - Pharmaceutical industry news". The Pharma Letter. 17 May 2000. 
  83. Hitti, Miranda (20 November 2007). "FDA OKs Abilify for Depression". WebMD. 
  84. Keating, Gina (23 November 2009). "FDA OKs Abilify for child autism irritability". Reuters. 
  85. 85.0 85.1 "Patent and Exclusivity Search Results". U.S. Food and Drug Administration (FDA). 
  86. 86.0 86.1 Mitchell, Max (December 8, 2016). "Bristol-Myers Squibb Agrees to $19.5M Settlement Over Abilify Marketing". The Legal Intelligencer. 
  87. "ABILIFY Label, Section 2.3 pp. 7–8". U.S. Food and Drug Administration (FDA).,021713s16,021729s8,021866s8lbl.pdf. 
  88. Staton, Tracy. "Pharma's Top 11 Marketing Settlements: Bristol-Myers Squibb - Abilify". FiercePharma. 
  89. "Press Release: Lundbeck and Otsuka Pharmaceutical sign historic agreement to deliver innovative medicines targeting psychiatric disorders worldwide (OMX:LUN)". Lundbeck. November 11, 2011. 
  90. Megan Brooks (2014-01-30). "Top 100 Selling Drugs of 2013". Medscape. 
  91. "BMS cuts salesforce on revised Abilify deal". PM Live. 7 November 2012. 
  92. Sagonowsky, Eric (December 1, 2016). "Lundbeck, Otsuka seek Abilify Maintena nod in bipolar disorder". FiercePharma. 
  93. "Abilify Maintena 300mg & 400mg powder and solvent for prolonged-release suspension for injection and suspension for injection in pre filled syringe - Summary of Product Characteristics (SPC)". UK Electronic Medicines Compendium. 
  94. "Barr Confirms Filing an Application with a Paragraph IV Certification for ABILIFY(R) Tablets" (Press release). Barr Pharmaceuticals, Inc. 2007-03-20. Retrieved 2008-12-23.
  95. Susan Decker; Tom Randall (2010-11-15). "Bristol-Myers Partner Otsuka Wins Abilify Ruling - Bloomberg Business". Bloomberg L.P.. 
  96. Oshiro, Yasuo; Sato, Seiji; Kurahashi, Nobuyuki, "Carbostyril derivatives", B1 EP patent application 0367141 B1, published 1996-10-01, assigned to Otsuka Pharmaceutical Co., Ltd.
  97. "Patent decision". UK Intellectual Property Office. 2006-09-19. 
  98. Michaelson, Jay (2014-11-09). "Mother's Little Anti-Psychotic Is Worth $6.9 Billion A Year". The Daily Beast. 
  99. "FDA approves first generic Abilify to treat mental illnesses". 
  100. "Teva Launches Generic Abilify Tablets in the United States".{72A03233-DF38-4F01-8A99-649C0ECC8F1C}. 
  101. "Aripiprazole Long-Acting Injectable Formulations for Schizophrenia: Aripiprazole Monohydrate and Aripiprazole Lauroxil". Expert Rev Clin Pharmacol 9 (2): 169–86. 2015. doi:10.1586/17512433.2016.1121809. PMID 26573020. 
  102. "Aristada (aripiprazole lauroxil) FDA Approval History". 
  103. Staton, Tracy (December 14, 2016). "Bristol-Myers to pay $19.5 million in Abilify off-label marketing settlement". FiercePharma. 
  104. "FDA approves pill with sensor that digitally tracks if patients have ingested their medication". U.S. Food and Drug Administration (FDA) (Press release). Retrieved 2017-11-29.
  105. Belluck, Pam (2017-11-13). "First Digital Pill Approved to Worries About Biomedical 'Big Brother'". The New York Times. ISSN 0362-4331. 
  106. Joint Formulary Committee. British National Formulary (BNF) 79. Pharmaceutical Pr; 2020.
  107. "Australian Medicines Handbook 2013 [Internet"]. 
  108. Truven Health Analytics, Inc. DRUGDEX® System (Internet) [cited 2013 Jun 25]. Greenwood Village, CO: Thomsen Healthcare; 2013.
  109. 109.0 109.1 109.2 "Classics in Chemical Neuroscience: Aripiprazole". ACS Chem Neurosci 8 (6): 1135–1146. June 2017. doi:10.1021/acschemneuro.7b00087. PMID 28368577. 
  110. 110.0 110.1 "Pharmacological and non-pharmacological treatment of adults with ADHD: a meta-review". Evid Based Ment Health 20 (1): 4–11. February 2017. doi:10.1136/eb-2016-102415. PMID 27993933. 
  111. 111.0 111.1 111.2 111.3 "Systematic review of clinical trials of aripiprazole for treating attention deficit hyperactivity disorder". Neurosciences (Riyadh) 18 (4): 323–9. October 2013. PMID 24141455. 
  112. "Alternative pharmacological strategies for adult ADHD treatment: a systematic review". Expert Rev Neurother 16 (2): 131–44. 2016. doi:10.1586/14737175.2016.1135735. PMID 26693882. 
  113. "Effectiveness of aripiprazole in treatment of adults with attention deficit disorder and restless legs syndrome". Int J Neuropsychopharmacol 11 (3): 439–40. May 2008. doi:10.1017/S1461145707008310. PMID 18208634. 
  114. 114.0 114.1 114.2 114.3 "Treatments for methamphetamine abuse: a literature review for the clinician". J Pharm Pract 24 (6): 541–50. December 2011. doi:10.1177/0897190011426557. PMID 22095579. 
  115. 115.0 115.1 115.2 115.3 "Aripiprazole, alcohol and substance abuse: a review". Eur Rev Med Pharmacol Sci 16 (10): 1346–54. October 2012. PMID 23104650. 
  116. 116.0 116.1 116.2 116.3 "Pharmacological approaches to methamphetamine dependence: a focused review". Br J Clin Pharmacol 69 (6): 578–92. June 2010. doi:10.1111/j.1365-2125.2010.03639.x. PMID 20565449. 
  117. 117.0 117.1 117.2 117.3 "Pharmacotherapy of methamphetamine addiction: an update". Subst Abus 29 (3): 31–49. 2008. doi:10.1080/08897070802218554. PMID 19042205. 

Further reading

External links